Clinical Trial

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to define the maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) of Tegavivint in combination with Gemcitabine in patients with relapsed or refractory osteosarcoma (OS). The study will also investigate the toxicities of Tegavivint in combination with gemcitabine in patients with relapsed or refractory OS.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-20; most recent amendment 2026-05-30.
Status change: Not Yet Recruiting → Recruiting 2026-02-27
Trial Details
NCT Number NCT07144254
Lead Sponsor Emory University
Collaborators: Iterion Therapeutics
Conditions Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma, Refractory Osteosarcoma
Enrollment 24 participants
Start Date 2026-01-22
Primary Completion 2028-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-02